Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2021 Aug;80(8):1102-1104.
doi: 10.1136/annrheumdis-2021-220088. Epub 2021 Mar 4.

Second COVID-19 infection in a patient with granulomatosis with polyangiitis on rituximab

Marcia A Friedman  1 , Kevin L Winthrop  2   3
Affiliations

Second COVID-19 infection in a patient with granulomatosis with polyangiitis on rituximab

Marcia A Friedman et al. Ann Rheum Dis. 2021 Aug.
No abstract available

Keywords: Covid-19; granulomatosis with polyangiitis; rituximab.

PubMed Disclaimer

Conflict of interest statement

Competing interests: KLW receives consulting fees from Pfizer, AbbVie, Union Chimique Belge (UCB), Eli Lilly & Company, Galapagos, GlaxoSmithKline (GSK), Roche, Gilead, BMS, Regeneron, Sanofi, AstraZeneca and Novartis.

Figures

Figure 1:
Figure 1:
Timeline of COVID-19 symptoms, testing, and relevant drugs: Timeline shown from August 28, 2020 until January 6, 2021. After the October 6th infection, COVID-19 symptoms completely recovered with the exception of ongoing fatigue. SARS-CoV-2 testing includes: October 8th positive rapid antigen assay, November 22nd negative rapid molecular test (®Abbot ID NOW), November 27th positive rapid molecular test (®BioFire FilmArray), and on January 6th a negative IgG test.
See this image and copyright information in PMC

Comment in

References

    1. Schulze-Koops H, Krueger K, Vallbracht I, et al. Increased risk for severe COVID-19 in patients with inflammatory rheumatic diseases treated with rituximab. Ann Rheum Dis 2020. doi: 10.1136/annrheumdis-2020-218075 [published Online First: 2020/06/28] - DOI - PubMed
    1. Loarce-Martos J, Garcia-Fernandez A, Lopez-Gutierrez F, et al. High rates of severe disease and death due to SARS-CoV-2 infection in rheumatic disease patients treated with rituximab: a descriptive study. Rheumatol Int 2020;40(12):2015–21. doi: 10.1007/s00296-020-04699-x [published Online First: 2020/09/19] - DOI - PMC - PubMed
    1. Yasuda H, Tsukune Y, Watanabe N, et al. Persistent COVID-19 Pneumonia and Failure to Develop Anti-SARS-CoV-2 Antibodies During Rituximab Maintenance Therapy for Follicular Lymphoma. Clin Lymphoma Myeloma Leuk 2020;20(11):774–76. doi: 10.1016/j.clml.2020.08.017 [published Online First: 2020/09/17] - DOI - PMC - PubMed
    1. Lancman G, Mascarenhas J, Bar-Natan M. Severe COVID-19 virus reactivation following treatment for B cell acute lymphoblastic leukemia. J Hematol Oncol 2020;13(1):131. doi: 10.1186/s13045-020-00968-1 [published Online First: 2020/10/04] - DOI - PMC - PubMed
    1. Hanson KE, Caliendo AM, Arias CA, et al. The Infectious Diseases Society of America Guidelines on the Diagnosis of COVID-19: Molecular Diagnostic Testing. Clin Infect Dis 2021. doi: 10.1093/cid/ciab048 [published Online First: 2021/01/23] - DOI - PMC - PubMed

Publication types

MeSH terms